title: [Side effects of the combined antiviral therapy in patients with chronic hepatitis C].
abstract: The aim of the study is to reveal and treat the side effects of the combined antiviral therapy - Peginterferon and Ribavirin in patients with chronic Hepatitis C. During 2004-2006 years, 40 patients in the ambulatory department of the Infectious Diseases Clinic of the State Medical University were investigated. All the patients were administered pegilated interferon and ribavirin after special procedures. The following side effects on the antiviral treatment were grouped: flu-like, cardiovascular, gastrointestinal, neuro-psychiatric, dermatological and hematological. Frequency, severity and duration of all unfavorable symptoms were independent of Hepatitis C genotype, though the adherence to the medications was better in younger age groups and the dose correction where required after the age 45.
authors.forename: E T
authors.initials: ET
authors.lastname: Vashakidze
authors.forename: T N
authors.initials: TN
authors.lastname: Gegeshidze
authors.forename: M T
authors.initials: MT
authors.lastname: Zhamutashvili
authors.forename: M B
authors.initials: MB
authors.lastname: Svanidze
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a